Sona Nanotech, Inc (TSE:SONA) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Sona Nanotech Inc. has announced promising results in a murine breast cancer study, where its combined targeted hyperthermia therapy and interleukin-2 treatment led to systemic immune responses and tumor shrinkage, including in untreated tumors. This rare abscopal effect indicates potential for enduring cancer treatment benefits. The company is moving towards additional studies and regulatory steps for potential human trials.
For further insights into TSE:SONA stock, check out TipRanks’ Stock Analysis page.